WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (International Agency for Research on Cancer, 2017. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, pp.2391-2405, 2016. ,
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries, Leukemia, vol.29, pp.1336-1343, 2015. ,
Epidemiology of chronic myeloid leukaemia: an update, Ann. Hematol, vol.94, issue.2, pp.241-247, 2015. ,
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med, vol.344, pp.1084-1086, 2001. ,
The rising prevalence of chronic myeloid leukemia in France, Leuk. Res, vol.69, pp.94-99, 2018. ,
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study, Blood, vol.118, pp.4331-4337, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-02299262
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population, J. Clin. Oncol, vol.34, pp.2851-2857, 2016. ,
Sur la resorption du pusaet sur l'alteration du sang dans les maladies clinique de persection nenemant. Premier observation, Rev Med, vol.2, p.216, 1827. ,
Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood, Edinburgh Med Sug J, vol.64, pp.413-423, 1845. ,
, Frorieps Notizen, vol.36, pp.151-156, 1845.
A minute chromosome n human chronic granualocytic leukemia, Science, vol.132, pp.1497-1501, 1960. ,
Clonal origin of chronic myelocytic leukemia in man, Proc. Natl. Acad. Sci. U.S.A, vol.58, pp.1468-1471, 1967. ,
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, vol.243, pp.290-293, 1973. ,
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.300, pp.765-767, 1982. ,
Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia, Nature, vol.306, pp.239-242, 1983. ,
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.306, pp.277-280, 1983. ,
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell, vol.36, pp.93-99, 1984. ,
Structural organization of the bcr gene and its role in the Ph' translocation, Nature, vol.315, pp.758-761, 1985. ,
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature, vol.315, pp.550-554, 1985. ,
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science, vol.247, pp.824-830, 1990. ,
Chronic myeloid leukemia: reminiscences and dreams, Haematologica, vol.101, pp.541-558, 2016. ,
, , 2014.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med, vol.2, pp.561-566, 1996. ,
The biology of chronic myeloid leukemia, N. Engl. J. Med, vol.341, pp.164-172, 1999. ,
Chronic myeloid leukemia: mechanisms of blastic transformation, J. Clin. Invest, vol.120, pp.2254-2264, 2010. ,
The biology of CML blast crisis, Blood, vol.103, pp.4010-4022, 2004. ,
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML, N. Engl. J. Med, vol.351, pp.657-667, 2004. ,
European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood, vol.122, p.872, 2013. ,
Prognostic discrimination in 'good-risk' chronic granulocytic leukemia, Blood, vol.63, pp.789-799, 1984. ,
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1, J Natl Compr Canc Netw, vol.14, pp.1505-1512, 2016. ,
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score, Blood, vol.118, pp.686-692, 2011. ,
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia, vol.30, pp.48-56, 2016. ,
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia, Leukemia, vol.26, pp.2254-2259, 2012. ,
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: longterm observation of 1151 patients from the randomized CML Study IV, Blood, vol.118, pp.6760-6768, 2011. ,
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis, Blood, vol.120, pp.761-767, 2012. ,
, Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group, J. Natl. Cancer Inst, vol.89, pp.1616-1620, 1997.
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N. Engl. J. Med, vol.337, pp.223-229, 1997. ,
The interferon-alpha revival in CML, Ann. Hematol, vol.94, issue.2, pp.195-207, 2015. ,
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the, Blood, vol.94, pp.1517-1536, 1999. ,
Three decades of transplantation for chronic myeloid leukemia: what have we learned?, Blood, vol.117, pp.755-763, 2011. ,
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase, J. Clin. Oncol, vol.28, pp.1888-1895, 2010. ,
Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award, J Clin Invest, vol.121, pp.1227-1228, 2011. ,
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia, J. Clin. Oncol, vol.32, p.3077, 2014. ,
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.376, pp.917-927, 2017. ,
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosinekinase inhibitor era: analysis of patient data from six prospective clinical trials, Lancet Haematol, vol.2, pp.186-193, 2015. ,
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib, J. Natl. Cancer Inst, vol.103, pp.553-561, 2011. ,
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring, American Journal of Hematology, vol.93, pp.442-459, 2018. ,
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib, Blood, vol.114, pp.1126-1126, 2009. ,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med, vol.348, pp.994-1004, 2003. ,
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med, vol.362, pp.2260-2270, 2010. ,
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial, Journal of Clinical Oncology, vol.34, p.2333, 2016. ,
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N. Engl. J. Med, vol.362, pp.2251-2259, 2010. ,
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, J Clin Oncol, vol.36, pp.231-237, 2018. ,
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy, Blood, vol.109, pp.2303-2309, 2007. ,
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia, JCO, vol.26, pp.3204-3212, 2008. ,
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034, Am. J. Hematol, vol.91, pp.869-874, 2016. ,
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results, Blood, vol.117, pp.1141-1145, 2011. ,
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosomepositive chronic myeloid leukemia patients with resistance or intolerance to imatinib, Blood, vol.118, pp.4567-4576, 2011. ,
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial, Journal of Clinical Oncology, vol.30, p.3486, 2012. ,
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias, N. Engl. J. Med, vol.369, pp.1783-1796, 2013. ,
Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?, Clin Cancer Res, vol.20, pp.310-322, 2014. ,
Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia, Ann. Hematol, vol.94, issue.2, pp.149-158, 2015. ,
Pulmonary Arterial Hypertension in Patients Treated by DasatinibClinical Perspective, Circulation, vol.125, pp.2128-2137, 2012. ,
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure, J. Clin. Oncol, vol.25, pp.3908-3914, 2007. ,
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia, Blood, vol.120, pp.3898-3905, 2012. ,
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis, Leukemia, vol.27, pp.1310-1315, 2013. ,
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, vol.113, pp.5401-5411, 2009. ,
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib, J. Clin. Oncol, vol.28, pp.2381-2388, 2010. ,
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy, Blood, vol.117, pp.3733-3736, 2011. ,
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study, Br. J. Cancer, vol.107, pp.904-909, 2012. ,
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, vol.11, pp.1029-1035, 2010. ,
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia, J. Clin. Oncol, vol.35, pp.298-305, 2017. ,
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease, J. Clin. Oncol, vol.32, pp.424-430, 2014. ,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, pp.515-522, 2013. ,
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study, Leukemia, vol.31, pp.1525-1531, 2017. ,
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, J. Cancer Res. Clin. Oncol, vol.144, pp.945-954, 2018. ,
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, vol.129, pp.846-854, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02050833
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, Lancet Oncol, issue.18, p.30192, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01859932
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.28, pp.41-51, 2017. ,
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group, Cancer, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01860448
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction, Blood, vol.107, pp.4532-4539, 2006. ,
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival, Blood, vol.119, pp.1501-1510, 2012. ,
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease, Blood, vol.118, pp.3657-3660, 2011. ,
The chronic myeloid leukemia stem cell: stemming the tide of persistence, Blood, vol.129, pp.1595-1606, 2017. ,
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches, BioDrugs, vol.31, pp.143-149, 2017. ,
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis, Cancer Cell, vol.14, pp.485-493, 2008. ,
Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J. Med. Chem, vol.47, pp.6658-6661, 2004. ,
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res, vol.65, pp.4500-4505, 2005. ,
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants, Cancer Res, vol.66, pp.5790-5797, 2006. ,
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia, Eur J Clin Pharmacol, vol.72, pp.185-193, 2016. ,
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib, Leukemia, vol.22, pp.1200-1206, 2008. ,
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial, JCO, vol.27, pp.3472-3479, 2009. ,
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, Blood, vol.109, pp.3207-3213, 2007. ,
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION), Blood, vol.123, pp.494-500, 2014. ,
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial, Blood, vol.109, pp.5143-5150, 2007. ,
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib, Haematologica, vol.95, pp.232-240, 2010. ,
Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized Optim dasatinib trial, FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100, vol.99, pp.237-238, 2014. ,
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib, Ann Hematol, vol.92, pp.1345-1350, 2013. ,
Clinical Impact of Dose Reductions and Interruptions of Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukaemia, Br J Haematol, vol.150, pp.303-312, 2010. ,
Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia, Geriatrics & gerontology international, vol.16, pp.768-770, 2016. ,
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results, Blood, vol.108, pp.28-37, 2006. ,
, Common Terminology Criteria for Adverse Events (CTCAE) | Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP, p.28, 2018.
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J. Natl. Cancer Inst, vol.85, pp.365-376, 1993. ,
European Organisation for Research and Treatment of Cancer, EORTC QLQ-C30 Scoring Manual, 2001. ,
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure, J. Clin. Oncol, vol.11, pp.570-579, 1993. ,
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation, Health Qual Life Outcomes, vol.1, p.79, 2003. ,
Cancer patients' understanding of longitudinal EORTC QLQ-C30 scores presented as bar charts, Patient Education and Counseling, vol.99, pp.2012-2017, 2016. ,
Dasatinib dose management for the treatment of chronic myeloid leukemia ,
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial, Lancet Haematol, vol.4, pp.310-316, 2017. ,
, , p.23, 2018.
Moving treatment-free remission into mainstream clinical practice in CML, Blood, vol.128, pp.17-23, 2016. ,
Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?, J. Clin. Oncol, vol.32, pp.2821-2823, 2014. ,
Attempt to early discontinue dasatinib first line in chronic phase CML patients in early molecular response and included in the prospective OPTIM-dasatinib trial, FERRATA STORTI FOUNDATION VIA GIUSEPPE BELLI 4, 27100, vol.100, pp.230-230, 2015. ,
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia, International Journal of Hematology & Oncology/UHOD: Uluslararasi Hematoloji Onkoloji Dergisi, vol.22, 2012. ,
Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study, J Cancer Res Clin Oncol, vol.142, pp.1441-1447, 2016. ,
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry, Am. J. Hematol, vol.92, pp.125-128, 2017. ,
Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest, Clin Lymphoma Myeloma Leuk, vol.17, pp.457-462, 2017. ,
, Traitement de maintenance par des doses alternées de dasatinib dans la leucémie myéloïde chronique Résumé : Les inhibiteurs de tyrosine kinase (ITKs) induisent des réponses durables chez les patients atteints de leucémie myéloïde chronique (LMC)
, L'objectif principal de notre étude était de déterminer la survie sans perte de la RMM (BCR-ABL1 IS >0.1%) en maintenance dans une cohorte rétrospective R puis par un essai prospectif P
, La durée médiane d'administration du dasatinib était de 44.8 (5.6 -116) et 47.8 (32.7 -88.4) mois et la dose médiane quotidienne de 50 et 100 mg dans les cohortes R et P respectivement. Avec un suivi médian de 24 et 30.7 mois dans les cohortes R et P, la survie sans perte de la RMM à 2 ans était de 80, Une cohorte de 100 patients a été étudiée dont 64 dans la cohorte R et 36 dans la cohorte P (critères d'inclusion identiques à ceux de l'étude d'arrêt EUROSKI soit au moins 3 ans de traitement et 1 an de RM 4 )
, La maintenance apparait comme une alternative à l'arrêt du dasatinib chez les patients en 1 ère ou seconde ligne
, Mots clés : leucémie myéloïde chronique, inhibiteurs de tyrosine kinase, réponse moléculaire, maintenance. Maintenance therapy with dasatinib administrated every other day in chronic myeloid leukemia Abstract: Tyrosine kinase inhibitors (TKIs) induce deep lasting molecular responses in patients with chronic myeloid leukemia (CML). However, 60% of patients eligible to TKIs discontinuation will experience loss of major molecular response (MMR). We evaluated maintenance therapy with dasatinib administrated every other day as an alternative to discontinuation